OptimizeRx Corporation (OPRX)
USD 7.44
(-5.58%)
USD 7.44
(-5.58%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 69.3 Million USD | 17.88% |
| 2022 | 51.25 Million USD | 45.3% |
| 2021 | 35.27 Million USD | 34.44% |
| 2020 | 26.24 Million USD | 37.15% |
| 2019 | 19.13 Million USD | 59.09% |
| 2018 | 12.02 Million USD | 48.79% |
| 2017 | 8.08 Million USD | 37.66% |
| 2016 | 5.87 Million USD | 39.94% |
| 2015 | 4.19 Million USD | 7.37% |
| 2014 | 3.9 Million USD | 31.4% |
| 2013 | 2.97 Million USD | 23.25% |
| 2012 | 2.41 Million USD | -5.94% |
| 2011 | 2.56 Million USD | 33.81% |
| 2010 | 1.91 Million USD | -28.29% |
| 2009 | 2.67 Million USD | 67.98% |
| 2008 | 1.59 Million USD | 248.87% |
| 2007 | 456.25 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 16.16 Million USD | -18.62% |
| 2024 Q2 | 14.38 Million USD | -11.05% |
| 2023 FY | 60.42 Million USD | 17.88% |
| 2023 Q3 | 13.35 Million USD | 5.09% |
| 2023 Q4 | 19.86 Million USD | 48.76% |
| 2023 Q1 | 14.49 Million USD | 8.84% |
| 2023 Q2 | 12.7 Million USD | -12.34% |
| 2022 Q1 | 11.86 Million USD | 0.78% |
| 2022 Q4 | 13.31 Million USD | 1.07% |
| 2022 FY | 51.25 Million USD | 45.3% |
| 2022 Q2 | 12.89 Million USD | 8.73% |
| 2022 Q3 | 13.17 Million USD | 2.16% |
| 2021 Q1 | 6.76 Million USD | -6.69% |
| 2021 FY | 35.27 Million USD | 34.44% |
| 2021 Q2 | 7.7 Million USD | 13.92% |
| 2021 Q3 | 9.03 Million USD | 17.32% |
| 2021 Q4 | 11.77 Million USD | 30.22% |
| 2020 Q1 | 6.6 Million USD | -2.79% |
| 2020 FY | 26.24 Million USD | 37.15% |
| 2020 Q3 | 6.19 Million USD | -0.14% |
| 2020 Q2 | 6.2 Million USD | -6.09% |
| 2020 Q4 | 7.24 Million USD | 17.06% |
| 2019 Q3 | 4.68 Million USD | 22.05% |
| 2019 FY | 19.13 Million USD | 59.09% |
| 2019 Q1 | 3.49 Million USD | -17.19% |
| 2019 Q4 | 6.79 Million USD | 44.94% |
| 2019 Q2 | 3.83 Million USD | 9.88% |
| 2018 Q4 | 4.21 Million USD | 44.32% |
| 2018 FY | 12.02 Million USD | 48.79% |
| 2018 Q3 | 2.92 Million USD | 12.9% |
| 2018 Q2 | 2.58 Million USD | 12.36% |
| 2018 Q1 | 2.3 Million USD | -16.59% |
| 2017 Q3 | 2.02 Million USD | 24.39% |
| 2017 Q4 | 2.76 Million USD | 36.18% |
| 2017 Q1 | 1.66 Million USD | -12.5% |
| 2017 Q2 | 1.63 Million USD | -1.8% |
| 2017 FY | 8.08 Million USD | 37.66% |
| 2016 Q1 | 1.22 Million USD | -17.94% |
| 2016 Q3 | 1.31 Million USD | -8.45% |
| 2016 Q2 | 1.43 Million USD | 16.64% |
| 2016 Q4 | 1.89 Million USD | 44.67% |
| 2016 FY | 5.87 Million USD | 39.94% |
| 2015 Q2 | 980.65 Thousand USD | 16.38% |
| 2015 Q4 | 1.49 Million USD | 71.02% |
| 2015 Q3 | 875.42 Thousand USD | -10.73% |
| 2015 FY | 4.19 Million USD | 7.37% |
| 2015 Q1 | 842.6 Thousand USD | 18.21% |
| 2014 Q3 | 1.15 Million USD | 19.53% |
| 2014 Q4 | 712.79 Thousand USD | -38.34% |
| 2014 FY | 3.9 Million USD | 31.4% |
| 2014 Q1 | 1.07 Million USD | 52.75% |
| 2014 Q2 | 967.07 Thousand USD | -9.78% |
| 2013 FY | 2.97 Million USD | 23.25% |
| 2013 Q1 | 733.96 Thousand USD | 16.17% |
| 2013 Q4 | 701.75 Thousand USD | -28.79% |
| 2013 Q2 | 552.76 Thousand USD | -24.69% |
| 2013 Q3 | 985.5 Thousand USD | 78.29% |
| 2012 Q2 | 591.62 Thousand USD | -6.14% |
| 2012 Q1 | 630.32 Thousand USD | -43.74% |
| 2012 FY | 2.41 Million USD | -5.94% |
| 2012 Q4 | 631.78 Thousand USD | 12.96% |
| 2012 Q3 | 559.3 Thousand USD | -5.46% |
| 2011 Q3 | 482.63 Thousand USD | -2.13% |
| 2011 Q1 | 469.28 Thousand USD | 117.03% |
| 2011 Q2 | 493.15 Thousand USD | 5.09% |
| 2011 Q4 | 1.12 Million USD | 132.15% |
| 2011 FY | 2.56 Million USD | 33.81% |
| 2010 Q1 | 263.09 Thousand USD | -35.51% |
| 2010 Q3 | 545.88 Thousand USD | -38.81% |
| 2010 FY | 1.91 Million USD | -28.29% |
| 2010 Q2 | 892.08 Thousand USD | 239.07% |
| 2010 Q4 | 216.22 Thousand USD | -60.39% |
| 2009 Q4 | 407.95 Thousand USD | -23.61% |
| 2009 FY | 2.67 Million USD | 67.98% |
| 2009 Q3 | 534.06 Thousand USD | 50.25% |
| 2009 Q2 | 355.46 Thousand USD | -74.17% |
| 2009 Q1 | 1.37 Million USD | 44.35% |
| 2008 Q1 | 266.1 Thousand USD | 0.0% |
| 2008 Q3 | 162.51 Thousand USD | -25.77% |
| 2008 Q2 | 218.92 Thousand USD | -17.73% |
| 2008 FY | 1.59 Million USD | 248.87% |
| 2008 Q4 | 953.45 Thousand USD | 486.67% |
| 2007 FY | 456.25 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Omnicell, Inc. | 534.79 Million USD | 87.042% |
| Renalytix Plc | 29.04 Million USD | -138.634% |
| Schrödinger, Inc. | 318.14 Million USD | 78.217% |
| Simulations Plus, Inc. | 37.02 Million USD | -87.201% |
| SOPHiA GENETICS SA | 117.73 Million USD | 41.14% |
| Streamline Health Solutions, Inc. | 31.19 Million USD | -122.192% |
| BrightSpring Health Services, Inc. Common Stock | 1.28 Billion USD | 94.614% |
| CareCloud, Inc. | 93.35 Million USD | 25.767% |
| HealthEquity, Inc. | 401.74 Million USD | 82.75% |
| iCoreConnect Inc. | 15.12 Million USD | -358.22% |
| Inovalon Holdings, Inc. | 427.99 Million USD | 83.808% |
| Ontrak, Inc. | 29.47 Million USD | -135.12% |
| Minerva Surgical, Inc. | 58.14 Million USD | -19.196% |
| Nutex Health, Inc. | 66.54 Million USD | -4.138% |
| OneMedNet Corporation | 8.24 Million USD | -740.392% |
| Progyny, Inc. | 176.61 Million USD | 60.761% |
| Augmedix, Inc. | 40.3 Million USD | -71.943% |
| CareCloud, Inc. | 93.35 Million USD | 25.767% |
| GE HealthCare Technologies Inc. | 5.48 Billion USD | 98.737% |
| Sharecare, Inc. | 225.97 Million USD | 69.332% |
| Aclarion, Inc. | 4.87 Million USD | -1321.38% |
| CareMax, Inc. | 670.05 Million USD | 89.657% |
| Bullfrog AI Holdings, Inc. Common Stock | 5.42 Million USD | -1176.902% |
| Forian Inc. | 20.59 Million USD | -236.427% |
| Bullfrog AI Holdings, Inc. Warrants | 5.42 Million USD | -1176.902% |
| HeartBeam, Inc. | 15.31 Million USD | -352.538% |
| GeneDx Holdings Corp. | 224.28 Million USD | 69.101% |
| SCWorx Corp. | 2.71 Million USD | -2448.098% |
| Definitive Healthcare Corp. | 546.47 Million USD | 87.318% |
| 10x Genomics, Inc. | 674.94 Million USD | 89.732% |
| Zhongchao Inc. | 13.92 Million USD | -397.768% |
| Accolade, Inc. | 306.51 Million USD | 77.39% |
| MSP Recovery, Inc. | 565.43 Million USD | 87.744% |
| R1 RCM Inc. | 336.6 Million USD | 79.411% |
| Spok Holdings, Inc. | 90.97 Million USD | 23.827% |
| Privia Health Group, Inc. | 134.31 Million USD | 48.405% |
| EUDA Health Holdings Limited | 4.8 Million USD | -1342.843% |
| TruBridge, Inc. | 206.17 Million USD | 66.386% |
| BrightSpring Health Services, Inc. Tangible Equity Unit | 1.28 Billion USD | 94.614% |
| Sharecare, Inc. | 225.97 Million USD | 69.332% |
| Health Catalyst, Inc. | 258.73 Million USD | 73.215% |
| GoodRx Holdings, Inc. | 710.34 Million USD | 90.244% |
| Premier, Inc. | 683.65 Million USD | 89.863% |
| HealthStream, Inc. | 168.02 Million USD | 58.755% |
| Certara, Inc. | 254.08 Million USD | 72.725% |
| GeneDx Holdings Corp. | 224.28 Million USD | 69.101% |
| Ontrak, Inc. | 29.47 Million USD | -135.12% |
| SHL Telemedicine Ltd. | 34.26 Million USD | -102.24% |
| CareCloud, Inc. | 93.35 Million USD | 25.767% |
| EUDA Health Holdings Limited | 4.8 Million USD | -1342.843% |
| HeartBeam, Inc. | 15.31 Million USD | -352.538% |
| Mangoceuticals, Inc. | 9.65 Million USD | -618.123% |
| CareMax, Inc. | 670.05 Million USD | 89.657% |
| Healthcare Triangle, Inc. | 18.12 Million USD | -282.354% |
| National Research Corporation | 52.52 Million USD | -31.953% |
| Aclarion, Inc. | 4.87 Million USD | -1321.38% |